GH Research PLC (GHRS) Price

GH Research Soars 19% on FDA Approval for Depression Drug Trial

Shares of biotech firm GH Research (GHRS) increased by 19% after the U.S. Food and Drug Administration (FDA) authorized it to resume testing its depression drug on January 5, 2026.